Industries: Biotech & Pharma
Funding stage: Series B (5 M EUR - < 20 M EUR) Founded: 2000 Employees: -
Business model: - Target: -
ORYZON is a clinical stage biopharmaceutical company that discovers and develops innovative epigenetics-based therapeutics for patients with cancer and neurodegenerative disorders. We are able to identify biomarkers through our genomics and proteomics platforms and to translate them in advanced and personalized therapies.
Initial public offering 100%
Capital Increase 19%
Investors: MAB-CAPITAL FUND, UNDISCLOSED PRIVATE INVESTORS
Minority stake unknown 6,5%
Investors: CORPORACION SANT BERNAT SCR SA, LABORATORIOS ORDESA SL
Source: Press releases , newsletters & platforms , company websites , annual reports & accounts , regulatory body sites & stock exchanges
We are continually updating our list of new startups so please let us know if you have recently started one.